Smell identification function in early-onset Alzheimer's disease and mild cognitive impairment by Velayudhan, Latha et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1017/S1041610218001503
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Velayudhan, L., Wilson-Morkeh, F., Penney, E., Jesu, A. J. M., Baillon, S., & Brugha, T. (2018). Smell
identification function in early-onset Alzheimer's disease and mild cognitive impairment. International
Psychogeriatrics, 1-6. https://doi.org/10.1017/S1041610218001503
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
SMELL IDENTIFICATION FUNCTION IN EARLY ONSET ALZHEIMER’S DISEASE AND MILD 
COGNITIVE IMPAIRMENT 
 
*Dr Latha Velayudhan  
Senior Clinical Lecturer and Consultant Psychiatrist  
Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neurosciences, De 
Crespigny Park, London, United Kingdom, SE5 8AF.  
Psychiatry for elderly, Department of Health Sciences, College of Medicine, Biological 
Sciences and Psychology, University of Leicester, Centre for Medicine, University Road, 
Leicester, United Kingdom, LE1 7RH.                                               
Email: Latha.Velayudhan@kcl.ac.uk 
 
Frances Wilson-Morkeh   
Psychiatry for elderly, Department of Health Sciences, College of Medicine, Biological Sciences 
and Psychology, University of Leicester, Centre for Medicine, University Road, Leicester, 
United Kingdom, LE1 7RH.  
Email: wilsonmork.fj@gmail.com 
 
Emily Penney   
Psychiatry for elderly, Department of Health Sciences, College of Medicine, Biological Sciences 
and Psychology, University of Leicester, Centre for Medicine, University Road, Leicester, 
United Kingdom, LE1 7RH.  
Email: ep194@student.le.ac.uk 
 
1Dr Amala Jovia Maria Jesu  
Specialist Trainee, Evington Centre, Leicestershire Partnership NHS Trust, Leicester, United 
Kingdom LE5 4QG 
Email: ajmj753@yahoo.co.uk 
 
Dr Sarah Baillon  
Psychiatry for elderly, Department of Health Sciences, College of Medicine, Biological Sciences 
and Psychology, University of Leicester, Centre for Medicine, University Road, Leicester, 
United Kingdom, LE1 7RH.  
Evington Centre, Leicestershire Partnership NHS Trust, Leicester, United Kingdom LE5 4QG 
Email: sfb5@leicester.ac.uk 
 
Prof Traolach Brugha  
Psychiatry for elderly, Department of Health Sciences, College of Medicine, Biological Sciences 
and Psychology, University of Leicester, Centre for Medicine, University Road, Leicester, 
United Kingdom, LE1 7RH.  
 
*Corresponding author and address for reprints: 
Dr Latha Velayudhan 
Consultant Psychiatrist and Senior Clinical Lecturer  
Department of Old Age Psychiatry 
Box PO 70 
Institute of Psychiatry, Psychology and Neuroscience 
2 
 
De Crespigny Park 
London 
United Kingdom 
SE5 8AF 
 
Tel:  0044 207848 0508 
E-mail:  latha.velayudhan@kcl.ac.uk; lv24@le.ac.uk 
 
Footnote: 
1Consultant Psychiatrist, South Staffordshire and Shropshire Healthcare NHS Foundation 
Trust, 1st Floor, The friary centre, Trent Valley Road, Lichfield, United Kingdom, WS13 6EF.  
 
Competing financial interests: None 
 
Abstract: 195 words  
Text: 1800 words 
2 Tables and 28 references 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract  
Little is known about olfactory identification (OI) function in Early Onset Alzheimer’s disease 
(EOAD) and early onset Mild Cognitive Impairment (eoMCI) with age of onset <65 years. We 
aimed to study OI in EOAD compared to eoMCI and age-matched healthy controls (HC). 19 
EOAD subjects with mild to moderate dementia, 17 with eoMCI and 21 HC recruited as 
convenience sample from memory services were assessed for cognition, behavioral 
symptoms and activities for daily living. The OI was tested using University of Pennsylvania 
smell identification test (UPSIT). EOAD participants performed worse compared to eoMCI 
and HC's on cognitive tests and OI (p<0.001). Although eoMCI had poorer cognitive scores 
compared to HC, they were similar in their OI function. OI correlated with attention 
(r=0.494, p=0.031), executive functions (r=0.508, p=0.026) and praxis (r= 0.455, p=0.05) 
within EOAD group. OI impairment was significantly associated with the diagnosis of EOAD 
versus eoMCI, but not with eoMCI when compared with HC. OI could potentially be useful in 
differentiating EOAD from eoMCI. Studies with late-life MCI patients showing OI impairment 
relative to HC may be attributed to a different disease process. Independent replication in 
larger sample is needed to validate these findings. 
 
Key words: Alzheimer’s disease, early onset dementia, smell identification, olfaction, mild 
cognitive impairment 
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INTRODUCTION  
Olfactory dysfunction in general and impaired olfactory identification (OI) in particular have 
been reported in Alzheimer’s disease (AD) and are found to occur at early stages of the 
disease (Mesholam et al., 1998). It has been indicated that involvement of the olfactory bulb 
and tract is one of the earliest events in the degenerative process on the central nervous 
system in AD (Christen-Zaech et al., 2003) and also that tau pathology in the olfactory bulb 
increases with severity of AD (Attems et al., 2005). All published reports of OI in AD have 
demonstrated deficits related to healthy controls (Rahayel et al., 2012) and its utility as a 
biomarker to predict cognitive decline and AD in elderly cognitively normal people and 
those with mild cognitive impairment (MCI) (Devanand et al., 2015; Lafaille-Magnan et al., 
2017; Woodward et al., 2017). A recent meta-analysis has shown that OI amongst the 
olfactory deficits to be most impaired in MCI (average age 72.83 years) (Roalf et al., 2017). 
Strong correlations of OI with cognition in AD patients have been identified, showing the 
potential of OI testing as a disease and progression marker (Suzuki et al., 2004; Velayudhan 
et al., 2013).  
 
Early-onset dementia is defined as dementia starting before the age of 65, a cut off based 
on a social partition of retirement age rather than biological one (Rossor et al., 2010).  
Although it is well established that patients with late onset AD and elderly MCI perform 
significantly more poorly than matched controls in their olfactory identification function, 
there is little information on OI in people with early onset AD (EOAD) and early onset MCI 
(eoMCI) (<65 years) compared to control subjects. We aimed to establish differences in OI 
5 
 
function between people with EOAD, eoMCI and age-matched healthy controls (HC), and to 
study the association of OI function with cognition and non-cognitive symptoms. 
 
METHODS 
Subjects: 
Mild-moderate EOAD participants (Mini Mental State Examination score, MMSE; 15-25) 
(n=19) were recruited from Young Onset Dementia Assessment Service (YODAS) within 
Mental Health Services for Older People (MHSOP), Leicestershire Partnership National 
Health Service (NHS) Trust, UK. They had onset of symptoms and diagnosis of dementia < 65 
years of age. Diagnosis of probable AD was made according to the National Institute of 
Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria (McKhann et al., 1984). The exclusion 
criteria were dementia other than AD; history of psychiatric disorder, including substance 
abuse. 
eoMCI Participants (MMSE score 24-30) (n=17) aged < 65 years, were recruited following 
clinical diagnosis as per ICD 10 code (F06.7) from YODAS within MHSOP, Leicestershire 
Partnership NHS Trust, UK. Diagnosis of MCI was made following a semi structured interview 
with an experienced psychiatrist, comprehensive cognitive testing and dementia screen, 
including blood testing and neuroimaging. Exclusion Criteria included history of any type of 
dementia or psychiatric disorder. 
Healthy Controls (HC) (n=21) were recruited from a group of interested healthy volunteers 
(9 domestic partners, 4 first degree relatives and 8 unrelated volunteers) and were within 
+/- 5 years of age of the EOAD and eoMCI participants. They had no complaints of memory 
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or functional decline. They did not have diagnosis of dementia or MCI. The MMSE score 
range was 27-30.   
The exclusion criteria were those with diagnosis of dementia, significant neurological or 
psychiatric illness, significant unstable systematic illness or organ failure.  
All participants had either no history at all of cigarette smoking or had stopped smoking for 
20 years or more. They also did not have acute or chronic medical conditions that may 
affect cerebral functioning or other conditions known to affect olfactory functioning such as 
common cold, polyps. 
Informed consent or assent, as appropriate was taken from all the participants. The study 
had approval from East Midlands region NHS Research Ethics Committee and the 
recruitment was completed during the period 2013-2015. 
 
Assessments 
Assessment included cognitive testing with MMSE (Folstein et al., 1975) for all 3 groups and 
CAMCOG part of Cambridge Mental Disorders of the Elderly Examination (CAMDEX) (Roth et 
al., 1986) in addition for EOAD and eoMCI group. For non-cognitive symptoms 
Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) and Bristol Activities of Daily Living 
Scale (BADL) (Bucks et al., 1996) were used. University of Pennsylvania smell identification 
test (UPSIT) was used, a standardised test for OI (higher scores reflecting better 
performance) and for which prior evaluation has indicated high reliability (Doty et al., 1984).  
 
Data analysis was done using SPSS 22.0. Comparisons were made on demographic 
information, clinical characteristics, and cognitive and behavioural test results using the Chi-
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square test for categorical outcomes and student t-tests and Spearman rank correlations for 
continuous variables as appropriate. Logistic regression analysis was carried out with 
diagnosis (EOAD vs eoMCI and eoMCI vs HC) as the dependent variables and age, sex, 
education UPSIT, MMSE, CAMCOG and BADL as independent variables. 
 
RESULTS  
None of the patient participants had speech or language difficulties. All participants were 
White Europeans except for 3 EOAD patients (Asian), 5 eoMCI patients (1 Afro-Caribbean 
and 4 Asian) and 1 HC (Asian).  
The socio-demographic and clinical comparisons between the subjects with EOAD, eoMCI and 
the HC are as described in Table 1. The EOAD group scored lower on the MMSE (t(34) =-2.980, 
p=0.005) and UPSIT measures (t(34) =-4.153, p<0.001) than eoMCI and similarly scored lower 
on MMSE (t(38) =-5.389, p<0.001) and UPSIT  (t(38) =-3.448, p=0.001) compared to HC. The 
eoMCI participants scored lower than HC group on the MMSE (t(36)=-4.241, p<0.001); 
however, there was no difference between the two groups on UPSIT scores (t(36) =0.188, 
p=0.852). Total UPSIT scores correlated with MMSE (r= 0.462, p<0.001) and total CAMCOG 
(r= 0.509, p<0.001) for the EOAD and eoMCI groups. Within the EOAD group the total UPSIT 
scores correlated with MMSE (r=0.477 and p=0.039) and with CAMCOG subitems i.e., 
executive functions (r= 0.508, p= 0.026), attention (r= 0.494, p= 0.031) and praxis (r= 0.455, 
p= 0.050). 
Logistic regression analysis using both adjusted and unadjusted models showed that UPSIT 
was the only variable that significantly predicted the diagnosis of EOAD versus eoMCI (odds 
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ratio 1.25; 95% CI 1.006, 1.558; p= 0.04), over the cognitive measures (table 2A). Whereas 
MMSE predicted diagnosis of eoMCI versus HC. 
There were no sex differences in the UPSIT scores for the whole sample and individual 
groups. The UPSIT scores did not correlate with total NPI or total BADL for the EOAD group. 
 
DISCUSSION 
The study investigated OI deficits in early onset AD and MCI, an area where there is lack of 
data and is understudied. Albeit in a small sample, the findings of our study are interesting 
in that it shows impaired OI in people with EOAD compared to eoMCI and HC. Impairment in 
OI was significantly associated with EOAD diagnosis versus eoMCI, adjusting for age, sex, 
education, MMSE and CAMCOG. As previously identified in late onset AD (Velayudhan et al., 
2013), a strong relationship between olfaction and cognition was also found in EOAD 
subjects. There was no difference in UPSIT scores between eoMCI and HC subjects, i.e., 
eoMCI had no OI impairment. 
 
The mean UPSIT scores for our EOAD cohort was higher than seen in later onset AD studies 
(mean from 18.1 to 20.6) (Rahayel et al., 2012; Velayudhan et al., 2015). We found no sex 
differences for olfactory identification deficits which is in keeping with previous study 
(Djordjevic et al., 2008). None of the patient participants reported subjective impairment in 
olfaction voluntarily. Interestingly, only 6% of late onset AD patients were aware of their 
olfactory impairment, despite being identified in 90% (Doty et al., 1987). Also its now 
reported that in cognitively healthy participants, subjective loss of smell is an independent 
predictor of dementia onset (Stanciu et al., 2014) and mortality (Ekstrom et al., 2017), but in 
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cognitively compromised patients, smell deficits go unnoticed. 
  
UPSIT scores in eoMCI group in our study did not differ from HC contrary to the reports 
from previous studies albeit in older adults (Roalf et al., 2017). Without validation of these 
results, a link between olfaction and eoMCI cannot be ruled out, although presence of a 
different disease-causing process to that of elderly MCI could be considered. It is also 
interesting to note that eoMCI patients in our study had higher prevalence of TIA, MI and 
diabetes which are known risk factors for vascular cognitive impairment (table 1), and 
possibly our study eoMCI participants are not necessarily pre-AD or developing AD 
pathology.   
 
We found OI was associated with attention, executive function and praxis within EOAD 
group. Previous research has found a relationship between olfaction and 
attention/executive functioning in healthy older adults, MCI, and AD (Djordjevic et al., 2008; 
Lehrner et al., 2009; Makizako et al., 2014). Impairment in odour identification in mid-life 
(35–64 years) has been associated with slightly poorer performance on cognitive function 
tests of attention, processing speed and executive function (Schubert et al., 2013).  
 
Clinically, challenges are seen in AD diagnosis despite comprehensive guidelines (McKhann 
et al., 2011; WHO, 2015). This is particularly in younger patients where AD is uncommon 
and less likely to be considered as part of a differential diagnosis, especially in the absence 
of a suggestive family history. Subsequently, for many patients this can lead to a lengthy, 
drawn out period between initial symptoms of dementia and ultimate specialist referral and 
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diagnosis. Although current biomarkers are invaluable in AD diagnosis, many are expensive 
and particularly invasive procedures rendering them difficult for extensive use in screening 
for dementia.  The need to aid diagnosis ideally through cheap, non-invasive, reliable tools is 
apparent. OI testing has been suggested as a potential  tool  for increasing diagnostic 
accuracy in AD as a clinical biomarker adjunct (Wesson et al., 2010).  
 
The main limitation of the study is the small sample size. The limitations of this study 
include the cross-sectional design which prohibits determining causality or direction of the 
associations seen. A further limitation, which could be overcome in future research, is to 
make additional comparisons with different groups, such as adults of a similar age with 
cognitive impairment with other neurodegenerative disorders. The strengths of this study 
include the well-defined participants and the use of standardized measures of odor 
identification and cognitive function that were administered by trained researchers. In 
addition, detailed demographic, health and behavioral data were available. 
 
In conclusion, albeit in a small sample, our study found impaired OI in people with EOAD 
compared to eoMCI and HC and also that OI impairment was significantly associated with a 
diagnosis of EOAD (versus eoMCI) while cognitive tests were not. OI in EOAD was associated 
with poorer performance in attention, executive functions and praxis. Further work, with 
larger cohorts, including people with different causes of cognitive impairment and in 
longitudinal studies is needed. This will give greater insight into the potential of OI testing 
used in combination with other diagnostic tests, for improving early detection of EOAD in 
clinical settings. 
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Table 1: Socio demographic clinical parameters comparison between people with early onset 
 Alzheimer’s disease (EOAD), early onset mild cognitive impairment (eoMCI) and healthy controls  
(HC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a EOAD vs eoMCI; b EOAD vs HC; c eoMCI vs HC (statistically significant between the groups, p<0.05) 
Values are mean (SD) or n (%) 
AD, Alzheimer’s disease; HC, healthy controls; eoMCI, early onset mild cognitive impairment, TIA, 
transient ischaemic attack; MI, myocardial infarction; MMSE, Mini Mental State Examination; CAMCOG, 
Cambridge Cognition Examination; UPSIT, University of Pennsylvania Smell Identification Test (higher 
UPSIT scores reflect better performance); BADL, Bristol Activities of daily living, NPI, Neuropsychiatric 
Inventory; n/a, not applicable; h/o, history of. 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
Mean (SD) or % 
EOAD (n=19) eoMCI (n=17) HC (n=21) 
Female  7 (36.8%) 6 (35.3%) 10 (47.6%) 
Age (years) 59.39 (5.3) 58.35 (4.1) 60.7 (11.2) 
Education (years) 11.59 (3.4) b 12.56 (2.7) c 15.5 (3) b, c 
Disease Duration (months) 3.5 (4) 3.3 (2) n/a 
Family h/o dementia   8 (42.1%) 7 (41.2%) 11 (52.4%) 
MMSE 21.89 (6.3) a, b 26.82 (2.6) a, c 29.43 (0.9) b, c 
CAMCOG total 74.47 (16.9) a 89.53 (7.8) a n/a 
Executive functions 19.53 (4.1) a 15.21 (4.9) a n/a 
40 UPSIT items 23.05 (6.6) a, b 31.47 (5.4) a 31.05 (7.9) b 
40 UPSIT, time taken (minutes) 24.13 (8.7) a, b 16.63 (6.2) a 17.88 (4.1) b 
BADL 8.74 (7.1) a 4.00 (4.5) a n/a 
NPI 16.0 (17.9) 15.77 (17.1) n/a 
Total carer’s distress 10.16 (9.4) 6.24 (7.2) n/a 
h/o diabetes mellitus  2 (10.5%) a 7 (41.2%) a, c 0 c 
h/o hypertension  4 (21.1%) 7 (41.2%) 7 (33.3%) 
h/o TIA   0 2 (11.8 %) a, c 0 
h/o MI   0 2 (11.8 %) a, c 0 
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Table 2: Multivariable logistic regression analyses for association of olfactory identification  
impairment using UPSIT with cognitive diagnosis of early onset Alzheimer’s disease (EOAD) versus  
early onset mild cognitive impairment (eoMCI), and eoMCI versus healthy controls (HC): Model 1-  
basic model and Model 2- adjusted for age, sex, education and other clinical measures. 
 
 
 
Model 1 included diagnosis of EOAD as the dependent variable and age, sex and education as 
independent variables  
Model 2 included diagnosis of EOAD as the dependent variable and sex, age, education, MMSE, total 
CAMCOG score, executive function scores and BADL as covariates in a multivariable logistic 
regression model. BADL, executive function and total CAMCOG are not available for model with 
outcome eoMCI vs. HC. 
 
OR, odds ratio; *, p < 0.05; CI, Confidence interval; MMSE, Mini Mental State Examination; CAMCOG, 
Cambridge Cognition Examination, UPSIT, University of Pennsylvania smell identification test; BADL, 
Bristol activities of daily living; N/A, Not applicable 
 
 
 A. EOAD vs. eoMCI 
OR (95% CI) 
 
P value 
B. eoMCI vs. HC 
OR (95% CI) 
 
P value 
   Model 1     
       Age 1.136 (0.899 to 1.434) 0.285 1.047 (0.938 to 1.168 0.415 
       Sex 1.088 (0.188 to 6.304) 0.925 2.602 (0.358 to 18.924, 
p= 0.345) 
 
       Education 1.115 (0.808 to 1.539) 0.506 1.461 (1.023 to 2.085) 0.037 * 
       UPSIT 1.284 (1.069 to 1.544) 0.008 * 0.990 (0.786 to 1.245) 0.928 
 
Model 2  
    
       Age 1.184 (0.878 to 1.596) 0.269 1.070 (0.901 to 1.271) 0.442 
       Sex 0.901 (0.086 to 9.414) 0.931 1.750 (0.091 to 33.678) 0.711 
       Education 1.106 (0.733 to 1.670) 0.631 1.109 (0.733 to 1.678) 0.625 
       UPSIT 1.252 (1.006 to 1.558) 0.044 * 0.827 (0.544 to 1.257)  0.374 
       MMSE 1.077 (0.595 to 1.949) 0.807 18.113 (1.036 to 316.724)  0.047 * 
      Total CAMCOG 1.096 (0.864 to 1.391) 0.450 N/A  
Executive functions 1.013 (0.751 to 1.364) 0.934 N/A  
       BADL 0.866 (0.672 to 1.116) 0.266 N/A  
